27. Deutscher Krebskongress
Deutsche Krebsgesellschaft e. V.
22. - 26.03.2006, Berlin
Lung Cancer
Meeting Abstract
(OP140)
[Volltext]
A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin), in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Reck M, Blumenschein Jr. G, Jotte R, von Pawel J, Miller WH, Khuri F, Rigas JR, Negro-Vilar A, Gatzemeier U[Volltext]
Meeting Abstract
(OP141)
[Volltext]
Long Term Results of Lung Cancer Treatment - Clinical and Population-Based Aspects
Schmidt M, Hölzel D[Volltext]
Meeting Abstract
(OP142)
[Volltext]
Hypofractionated stereotactic radiotherapy (hSRT) of NSCLC Stage I
Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Nieder C, Molls M[Volltext]
Meeting Abstract
(OP143)
[Volltext]
Identification of patients potentially benefiting from concomitant EGF-R inhibition and chemotherapy: CHALLENGE trial: Erlotinib followed by Gemcitabine/Cisplatin +/- Erlotinib induction in patients with NSCLC IIIA (N2)/IIIB (N3) monitored by microarray analyses
Overbeck TR, Danner B, Dörge H, Wenleder S, Hemmerlein B, Meller J, Baum RP, Wolf J, Schirren J, Müller RP, Wolf M, Griesinger F[Volltext]
Meeting Abstract
(OP144)
[Volltext]
Single-Agent (SA) Therapy of Docetaxel (D) and Gemcitabine (G) for Patients (pts) in Advanced Non-small Cell Lung Cancer (NSCLC): Results of Three Consecutive Randomized Multicentre Trials
Manegold C, Thatcher N, Kortsik C, Koschel G, Mezger J, Schott von Römer K, Pilz LR[Volltext]
Meeting Abstract
(OP145)
[Volltext]
Gefitinib for treatment of non small cell lung cancer (NSCLC): Single center clinical results and mutation analysis of the epidermal growth factor receptor (EGFR) kinase domain
Frickhofen N, Neugebauer B, Hengstler S, Labenz S, Fuhr HG, Schirren J, Fisseler-Eckhoff A, Serve H, Müller-Tidow C[Volltext]
Meeting Abstract
(OP146)
[Volltext]
First- and Secondline chemotherapy with Pemetrexed alone or in combination with Carboplatin in malignant pleural mesothelioma
Storbeck B, Gatzemeier U, Reck M[Volltext]
Meeting Abstract
(PO147)
[Volltext]
Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC – Interim results
Debus J, Hindermann S, Morr H, Mezger J, Sebastian M, Angermund R, Drings P[Volltext]
Meeting Abstract
(PO148)
[Volltext]
Intensity-modulated Radiotherapy (IMRT) of Lung Tumors in 50 Patients: Protection of Lung Tissue and low Toxicity
Huhnt W, Buchali A[Volltext]
Meeting Abstract
(PO149)
[Volltext]
Side effects of hypofractionated extracranial stereotactic radiotherapy (ESRT) of malignant tumours of the lung
Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Thamm R, Molls M[Volltext]
Meeting Abstract
(PO150)
[Volltext]
Sorafenib (BAY 43-9006) in Patients with Relapsed or Refractory Advanced Non-Small-Cell Lung Carcinoma – a phase II study
Reck M, Blumenschein Jr. G, Bernard I, Scheuring U, Gatzemeier U[Volltext]
Meeting Abstract
(PO151)
[Volltext]
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP)
Gauler TC, Tewes M, Sailer V, Bildat S, Schütt P, Korfee S, Stattaus J, Toetsch M, Seeber S, Eberhardt W[Volltext]
Meeting Abstract
(PO152)
[Volltext]
First experiences with oral tyrosine kinase inhibitor Erlotinib in patients with advanced Non small cell lung cancer within an Expanded Access Program (EAP Germany)
Schneider CP[Volltext]
Meeting Abstract
(PO153)
[Volltext]
Correlation of PTTG-1 expression with survival in small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC)
Geddert H, Rehfeld N, Atamna A, Rohrbeck A, Gabbert HE, Kronenwett R, Haas R, Rohr UP[Volltext]
Meeting Abstract
(PO154)
[Volltext]
Genetic-based classification of lung cancer: correlation between nuclear DNA content, chromosomal alterations and morphology
Amin Kotb WFM, Petersen I[Volltext]
Meeting Abstract
(PO155)
[Volltext]
Single-agent chemotherapy with Mitomycin for advanced non-small cell lung cancer patients with reduced Performance Status
Guschall WR, Dittrich I[Volltext]
Meeting Abstract
(PO156)
[Volltext]
Tumor specific MUC1 glycosylation correlates with improved post-surgical survival of non-small cell lung cancer patients with lymphatic or distant metastasis
Wiewrodt R, Kuemmel A, Single K, Bittinger F, Faldum A, Sebastian M, Taube C, Goletz S, Buhl R[Volltext]
Meeting Abstract
(PO157)
[Volltext]
Retrospective analysis of second-line chemotherapy in relapsed NSCLC patients who had received first-line paclitaxel/carboplatin chemotherapy in a randomized phase III trial
Nagel S, Raziq H, Blankenburg T, Schaedlich S, Schuette W[Volltext]
Meeting Abstract
(PO158)
[Volltext]
Predictive factors for patients with small cell lung carcinoma (SCLC) undergoing first-line ACE chemotherapy – results after long term follow-up of median 7.5 years
Brueckl WM, Herbst L, Lechler A, Zirlik S, Fuchs F, Brunner T, Klein P, Papadopoulos T, Hohenberger W, Hahn EG, Wiest GH[Volltext]
Meeting Abstract
(PO160)
[Volltext]
Successful in-patient rehabilitation of lung cancer patients - predictors and outcome
Riesenberg H, Lübbe AS[Volltext]
Meeting Abstract
(PO161)
[Volltext]
Fast response of chemotherapy-refractory bronchiolo-alveolar carcinoma to erlotinib
Gütz S, Schwartz EK, Gutjahr K, Gillissen A[Volltext]
Meeting Abstract
(PO162)
[Volltext]
Pulmonary mucinous cystadenocarcinoma – a rare disease successfully treated by thoracoscopic approach?
Möbius C, Ott R, Winkler J, Tannapfel A, Hauss J, Eichfeld U[Volltext]
Meeting Abstract
(PO163)
[Volltext]
Präoperatives Staging des nicht-kleinzelligen Bronchialkarzinoms mit PET/CT
Buck AK, Blumstein NM, Blümel C, Glatting G, Pauls S, Mottaghy FM, Halter G, Sunder-Plassmann L, Reske SR[Volltext]
Meeting Abstract
(PO164)
[Volltext]
Tumorgrading: An important prognostic factor in diagnostic of non-smal-cell-lung-cancer, stadium pT1
Neugebauer B, Schirren J, Beqiri S, Fisseler-Eckhoff A[Volltext]
